Diagnosing Lung Carcinomas with Optical Coherence Tomography
Overview
Authors
Affiliations
Rationale: Lung carcinoma diagnosis on tissue biopsy can be challenging because of insufficient tumor and lack of architectural information. Optical coherence tomography (OCT) is a high-resolution imaging modality that visualizes tissue microarchitecture in volumes orders of magnitude larger than biopsy. It has been proposed that OCT could potentially replace tissue biopsy.
Objectives: We aim to determine whether OCT could replace histology in diagnosing lung carcinomas. We develop and validate OCT interpretation criteria for common primary lung carcinomas: adenocarcinoma, squamous cell carcinoma (SCC), and poorly differentiated carcinoma.
Methods: A total of 82 ex vivo tumor samples were included in a blinded assessment with 3 independent readers. Readers were trained on the OCT criteria, and applied these criteria to diagnose adenocarcinoma, SCC, or poorly differentiated carcinoma in an OCT validation dataset. After a 7-month period, the readers repeated the training and validation dataset interpretation. An independent pathologist reviewed corresponding histology.
Measurements And Main Results: The average accuracy achieved by the readers was 82.6% (range, 73.7-94.7%). The sensitivity and specificity for adenocarcinoma were 80.3% (65.7-91.4%) and 88.6% (80.5-97.6%), respectively. The sensitivity and specificity for SCC were 83.3% (70.0-100.0%) and 87.0% (75.0-96.5%), respectively. The sensitivity and specificity for poorly differentiated carcinoma were 85.7% (81.0-95.2%) and 97.6% (92.9-100.0%), respectively.
Conclusions: Although these results are encouraging, they indicate that OCT cannot replace histology in the diagnosis of lung carcinomas. However, OCT has potential to aid in diagnosing lung carcinomas as a complement to tissue biopsy, particularly when insufficient tissue is available for pathology assessment.
Spatial lung imaging in clinical and translational settings.
Mahmutovic Persson I, Bozovic G, Westergren-Thorsson G, Rolandsson Enes S Breathe (Sheff). 2024; 20(3):230224.
PMID: 39360023 PMC: 11444490. DOI: 10.1183/20734735.0224-2023.
Yuan S, Xu C, Cui B, Zhang T, Liang B, Yuan W Nat Commun. 2024; 15(1):7680.
PMID: 39227604 PMC: 11372151. DOI: 10.1038/s41467-024-51633-x.
Rabindran B, Corben A Pathol Oncol Res. 2023; 29:1611167.
PMID: 37521364 PMC: 10374948. DOI: 10.3389/pore.2023.1611167.
Bouma B, de Boer J, Huang D, Jang I, Yonetsu T, Leggett C Nat Rev Methods Primers. 2023; 2.
PMID: 36751306 PMC: 9901537. DOI: 10.1038/s43586-022-00162-2.
Zhu Q, Yu H, Liang Z, Zhao W, Zhu M, Xu Y Front Oncol. 2022; 12:870556.
PMID: 36338729 PMC: 9634220. DOI: 10.3389/fonc.2022.870556.